In short
This article discusses a phase II clinical trial investigating the use of Adenovirus Vector Serotype 5 Containing The Vascular Endothelial Growth Factor D Isoform (AdVEGF-D) as a potential treatment for severe coronary artery disease. The study aims to evaluate the safety and effectiveness of this innovative gene therapy approach for patients with refractory angina who are not suitable candidates for traditional revascularization procedures.
At a glance
- Study Type
- Phase II randomized, double-blinded, placebo-controlled study
- Intervention
- AdVEGF-D regenerative gene transfer
- Target Population
- Patients with refractory angina unsuitable for revascularization
- Primary Objectives
- Evaluate safety and efficacy of gene therapy
- Secondary Objectives
- Assess effects on myocardial perfusion, symptoms, and quality of life
- Key Inclusion Criteria
- Age 30-85, significant angina (CCS 2-3), coronary stenosis ≥60%
- Key Exclusion Criteria
- Recent acute coronary events, severe left ventricular dysfunction, malignancy
- Primary Endpoints
- Improvement in 6-minute walking test and CCS class
- Administration Route
- Intracardiac use
What is VEGF-D Gene Therapy?
VEGF-D gene therapy is an innovative treatment being studied for patients with severe coronary artery disease, particularly those suffering from refractory angina. This therapy uses a modified virus called AdVEGF-D Delta N Delta C, also known as AdsVEGF-D, to deliver a gene that promotes the growth of new blood vessels in the heart.
How Does VEGF-D Gene Therapy Work?
The treatment involves injecting a specially designed adenovirus (a type of virus that has been modified for medical use) directly into the heart muscle. This virus carries a gene that produces a protein called Vascular Endothelial Growth Factor D (VEGF-D). VEGF-D stimulates the growth of new blood vessels, a process known as angiogenesis. By promoting the growth of new blood vessels, this therapy aims to improve blood flow to areas of the heart that are not receiving enough oxygen due to blocked or narrowed arteries.
Who Can Benefit from This Treatment?
This therapy is being developed for patients with severe coronary artery disease who experience persistent chest pain (angina) despite optimal medication. Specifically, it's intended for those who:
- Have significant angina (rated as CCS 2-3 on a scale that measures chest pain severity)
- Have significant narrowing (60% or more) in their coronary arteries
- Cannot undergo traditional treatments like bypass surgery (CABG) or angioplasty (PCI) due to the nature of their artery blockages
- Experience chest pain during a 6-minute walking test
These patients are often described as having refractory angina, meaning their chest pain persists despite standard treatments.
The ReGenHeart Clinical Trial
The VEGF-D gene therapy is currently being studied in a clinical trial called ReGenHeart. This is a Phase II randomized, double-blinded, placebo-controlled study. Here are some key points about the trial:
- It aims to evaluate the safety and effectiveness of the VEGF-D gene therapy in patients with refractory angina
- Participants are randomly assigned to receive either the actual treatment or a placebo
- Neither the patients nor the doctors know who is receiving the real treatment (this is what "double-blinded" means)
- The study will measure improvements in patients' ability to exercise, their symptoms, quality of life, and the safety of the treatment
To participate in the trial, patients must meet specific criteria, including being between 30 and 85 years old and having a certain level of heart function.
Potential Benefits of VEGF-D Gene Therapy
The researchers hope that this therapy will provide several benefits for patients with severe coronary artery disease:
- Improved exercise capacity: Measured by how far patients can walk in 6 minutes
- Reduced angina symptoms: Assessed using the Canadian Cardiovascular Society (CCS) classification
- Better heart blood flow: Evaluated through tests that measure heart perfusion
- Enhanced quality of life: By reducing chest pain and improving overall heart function
These potential benefits could significantly improve the daily lives of patients who have exhausted other treatment options.
Safety Considerations
As with any new medical treatment, safety is a top priority. The ReGenHeart trial has specific criteria to ensure patient safety:
- Patients with certain conditions are excluded, such as those with severe heart failure, recent heart attacks, or strokes
- People with current or suspected cancer cannot participate
- Patients with severe complications from diabetes, significant anemia, or kidney problems are also excluded
- The trial monitors for any side effects or complications throughout the study
It's important to note that this is still an experimental treatment, and its long-term effects are not yet fully known.